At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 355 enrolled
Drug / intervention
Abilify +1 moredrug
Likely dose
Abilify 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Mar 7, 2006·Updated Dec 30, 2011
In Brief
A Phase 4 clinical trial evaluating Abilify and Risperidal Consta for Schizophrenia and Psychotic Disorders. Completed, enrolled 355 participants.
Detailed Summary
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Psychotic Disorders
Countries--
CollaboratorsJanssen, LP
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedMar 2006
Primary CompletionJan 2009
TodayJul 2026
First PostedMar 7, 2006
Enrollment StartFeb 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.3 years ago
Interventions
Abilifydrug
10-30 mg once daily for 104 weeks
Risperidal Constadrug
25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks